Robbins LLP is Investigating Allegations that ImmunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product.

The Allegations:

According to the complaint, during the class period, defendant Soon-Shiong materially overstated Anktiva’s capabilities.

Plaintiff alleges that on March 24, 2026, a warning letter from the U.S. Food and Drug Administration regarding defendant Soon-Shiong's claims about Anktiva was publicized. The warning letter indicated that "the promotional communications create a misleading impression that Anktiva, a treatment for certain type of bladder cancer, can cure and even prevent all cancer."  The letter articulated additional false claims made by Soon-Shiong. On this news, ImmunityBio common stock fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

What Now: You may be eligible to participate in the class action against ImmunityBio, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.